$0.78—Stale · unknown old
NASDAQ • Last print unknown ago
$0.78—Stale · unknown old
Adamis Pharmaceuticals Corporation focuses on developing and commercializing specialty pharmaceuticals, particularly in the fields of respiratory and allergy treatments. Its competitive position is primarily driven by its proprietary drug delivery technologies and a niche focus on underserved markets, particularly in the U.S.
Adamis generates revenue through the sale of specialty pharmaceuticals, leveraging its proprietary drug delivery systems to differentiate its products. The company focuses on niche markets where competition is limited, allowing for higher pricing power despite its current financial struggles.
FDA approval of new drug applications, particularly in respiratory and allergy markets
Partnership announcements with larger pharmaceutical companies
Changes in competitive landscape, particularly from generic entrants
Market adoption rates of existing products
Regulatory changes that could affect drug approval processes or pricing
Technological disruption in drug delivery systems
Increased competition from generic drug manufacturers
Emergence of new therapies that could replace existing products
Negative cash flow and high operating losses impacting liquidity
Low current ratio indicating potential short-term liquidity issues
moderate - while healthcare spending is generally resilient, demand for specialty pharmaceuticals can be influenced by economic conditions affecting consumer spending and insurance coverage.
Higher interest rates could increase the company's cost of capital, impacting its ability to finance R&D and operations, potentially leading to lower valuations.
minimal - the company has a negative debt/equity ratio, indicating a reliance on equity financing rather than debt.
growth - investors looking for high-risk, high-reward opportunities in the biotech sector.
high - the stock has demonstrated significant volatility, with a 1-year return of -91.4%.